Oxford Immunotec Global (NASDAQ:OXFD): Q3 GAAP EPS of $0.04 beats by $0.07.
Revenue of $21.22M (+32.2% Y/Y) beats by $0.99M.
Shares -0.81% PM.
Tuesday, November 5, 2019
Becton, Dickinson FQ4 top line up 4%, non-GAAP EPS up 13%
Becton, Dickinson and Company (NYSE:BDX) fiscal Q4 results:
Revenues: $4,584M (+4.1%); BD Medical: $1,366M (+3.3%); BD Life Sciences: $502M (+4.4%); BD Interventional: $693M (+7.3%).
Net income: $112M (+164.7%); EPS: $0.41 (+164.1%); non-GAAP EPS: $3.31 (+13.0%).
Cash flow ops (FY): $3,330M (+16.2%).
Fiscal 2020 guidance: Revenue growth: 4.0 – 4.5%; non-GAAP EPS: $12.50 – 12.65.
resTORbio EPS misses by $0.14
resTORbio (NASDAQ:TORC): Q3 GAAP EPS of -$0.68 misses by $0.14.
Cash, equivalents and marketable securities of $117.3M.
Zimmer Biomet Q3 earnings up 166%
Zimmer Biomet Holdings (NYSE:ZBH) Q3 results:
Sales: $1,892.4M (+3.0%); Knees: $651.9M (+3.8%); Hips: $460.2M (+3.5%); S.E.T.: $437.7M (+5.6%); Spine & CMF: $181.3M (-2.0%).
Net income: $431.1M (+165.8%); EPS: $2.08 (+163.3%).
Cash flow ops: $577.9M (+19.4%).
2019 guidance unchanged.
Shares up 4% premarket on light volume.
Intra-Cellular Therapies EPS beats by $0.18
Intra-Cellular Therapies (NASDAQ:ITCI): Q3 GAAP EPS of -$0.63 beats by $0.18.
Cash, cash equivalents and investment securities of $255.4M
Allogene Therapeutics EPS beats by $0.05
Allogene Therapeutics (NASDAQ:ALLO): Q3 GAAP EPS of -$0.50 beats by $0.05.
Cash, equivalents and investments of $601.95M.
Subscribe to:
Comments (Atom)